- Home
- NTRA
NTRA
Natera Inc.
as 03-25-2025 12:35pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 18.4B | IPO Year: | 2015 |
| Target Price: | $179.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $83.13 - $183.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,696,911,000 | Revenue Growth: | 56.75% |
| Revenue Growth (this year): | 13.56% | Revenue Growth (next year): | 18.11% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Mar 17 '25 | Sell | $147.88 | 1,026 | $149,835.56 | 144,782 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Mar 17 '25 | Sell | $147.88 | 928 | $135,521.13 | 224,185 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Mar 17 '25 | Sell | $147.80 | 795 | $116,099.12 | 157,291 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Mar 17 '25 | Sell | $147.80 | 792 | $115,661.03 | 71,871 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Mar 17 '25 | Sell | $147.80 | 1,127 | $164,583.86 | 2,364,291 | |
| Sheena Jonathan | NTRA | Director | Mar 17 '25 | Sell | $145.94 | 5,881 | $856,410.26 | 258,949 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Mar 17 '25 | Sell | $146.03 | 6,702 | $978,677.65 | 203,354 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Mar 12 '25 | Sell | $147.39 | 50,000 | $7,385,248.66 | 2,364,291 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Mar 5 '25 | Sell | $143.56 | 6,000 | $859,734.20 | 144,782 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Mar 5 '25 | Sell | $143.78 | 87,272 | $12,515,005.94 | 203,354 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
Insider Monkey
2 days ago
Is Natera, Inc. (NTRA) the Best Diagnostics Stock to Invest in Right Now?
Insider Monkey
6 days ago
Here’s What Lifted Natera (NTRA) in Q4 and 2024
StockStory
6 days ago
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Insider Monkey
8 days ago
Is Natera (NTRA) the Best Biotech Stock According to Billionaires?
Argus Research
9 days ago
Daily – Vickers Top Buyers & Sellers for 03/17/2025
Simply Wall St.
12 days ago
Natera And 2 Other Stocks That May Be Trading Below Their Estimated Value
Simply Wall St.
12 days ago
Exploring Three High Growth Tech Stocks In The US Market
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.